Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07218770 · ClinicalTrials.gov registry record · Phase 1
A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants
A Phase 1 study of Active Noninfectious Uveitis Affecting the Posterior Segment, sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 2
- Study locations
NCT07218770: Recruiting Phase 1 study of Active Noninfectious Uveitis Affecting the Posterior Segment, sponsored by Regeneron Pharmaceuticals.
NCT07218770 is a Phase 1 study of Active Noninfectious Uveitis Affecting the Posterior Segment that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 72 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07218770, a Phase 1 study of Active Noninfectious Uveitis Affecting the Posterior Segment, is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is researching an experimental drug called REGN7041 (also referred to as "study drug"). The study is focused on patients who have active inflammation inside of the eye without any signs of infection. The aim of the study is to see how safe and tolerable the study drug is. This is the first time the study drug is being tested in humans. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood and the fluid in the eye at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Conditions Studied
Interventions
- DRUG REGN7041
Study Locations (2)
Illinois
- Illinois Retina Associates - Oak Park
Tennessee
- Tennessee Retina PC - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2025-12-17 |
| Est. Completion | 2028-06-28 |
| Phase | Phase 1 |
What NCT07218770 shows while recruiting
NCT07218770 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% higher).
The record links to 1 condition, with Active Noninfectious Uveitis Affecting the Posterior Segment appearing as the primary indexed condition, and to 1 intervention - of which REGN7041 is the first listed.
NCT07218770 reports a single indexed study location in Illinois, Tennessee.
Frequently Asked Questions
What is clinical trial NCT07218770 about?
NCT07218770 is a clinical study titled "A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants". This study is researching an experimental drug called REGN7041 (also referred to as "study drug"). The study is focused on patients who have active inflammation inside of the eye without any signs of infection. The aim of the study is to see how safe and tolerable the study drug is. This is the fir...
What is the current status of trial NCT07218770?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2025-12-17. Estimated completion is 2028-06-28.
What conditions does trial NCT07218770 study?
This clinical trial studies the following conditions: Active Noninfectious Uveitis Affecting the Posterior Segment.
What interventions are being tested in trial NCT07218770?
The interventions under investigation include: REGN7041 (DRUG).
Who is sponsoring clinical trial NCT07218770?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07218770 being conducted?
This trial has 2 study locations across Illinois, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07218770's enrollment target sits among peer trials
72 736th of 2000 higher than 1,254 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI